Cargando…

Oncogene addiction and tumor mutational burden in non‐small‐cell lung cancer: Clinical significance and limitations

Lung cancer incidence has increased worldwide over the past decades, with non‐small cell lung cancer (NSCLC) accounting for the vast majority (85%) of lung cancer specimens. It is estimated that lung cancer causes about 1.7 million global deaths per year worldwide. Multiple trials have been carried...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolle, Elisabeth, Leithner, Katharina, Olschewski, Horst
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2019
Materias:	Mini Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6997016/ https://www.ncbi.nlm.nih.gov/pubmed/31799812 http://dx.doi.org/10.1111/1759-7714.13246

Ejemplares similares

Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer
por: Smolle, Elisabeth, et al.
Publicado: (2020)

KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
por: Chen, Hanxiao, et al.
Publicado: (2020)

Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
por: Fischer, Carina, et al.
Publicado: (2015)

Phospholipid dynamics in ex vivo lung cancer and normal lung explants
por: Lesko, Julia, et al.
Publicado: (2021)

Immunotherapy in oncogene addicted non-small cell lung cancer
por: McLean, Luke, et al.
Publicado: (2021)

Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells
por: Leithner, Katharina, et al.
Publicado: (2014)

Oncogenic mutation or overexpression of oncogenic KRAS or BRAF is not sufficient to confer oncogene addiction
por: Ito, Reina E., et al.
Publicado: (2021)

Integrins, Oncogenes, and Anchorage Independence
por: Schwartz, Martin Alexander
Publicado: (1997)

TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers
por: Leithner, Katharina, et al.
Publicado: (2016)

Clinical significance of post‐progression survival in lung cancer
por: Imai, Hisao, et al.
Publicado: (2017)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
por: Calabrese, Fiorella, et al.
Publicado: (2022)

The Enigma of Atypical Cartilaginous Tumors: Surgery or Surveillance?
por: Leithner, Andreas, et al.
Publicado: (2023)

Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden
por: Salehi-Rad, Ramin, et al.
Publicado: (2021)

Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer
por: Turkaj, Ana, et al.
Publicado: (2018)

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
por: Ferrara, Miriam Grazia, et al.
Publicado: (2020)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited)
por: Patel, Priyanka, et al.
Publicado: (2020)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment
por: Remon, J., et al.
Publicado: (2018)

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities
por: Fountzilas, Elena, et al.
Publicado: (2018)

Comparison and discussion of the treatment guidelines for small cell lung cancer
por: Zhao, Honglin, et al.
Publicado: (2018)

Curative effect assessment of immunotherapy for non‐small cell lung cancer: The “blind area” of Immune Response Evaluation Criteria in Solid Tumors (iRECIST)
por: Song, Peng, et al.
Publicado: (2019)

The Role of Accumbal Hypoactivity in Cocaine Addiction.
por: Peoples, L. L., et al.
Publicado: (2007)

The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017)

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer
por: Attili, Ilaria, et al.
Publicado: (2018)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era
por: De Carlo, Elisa, et al.
Publicado: (2022)

Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
por: Su, Shu, et al.
Publicado: (2023)

Targeting STAT3 and oxidative phosphorylation in oncogene-addicted tumors
por: Lee, Matilda, et al.
Publicado: (2018)

Targeting of non-oncogene addiction
por: Igea, Ana, et al.
Publicado: (2015)

Advances in study of the sequence of lung tumor biopsy and thermal ablation
por: Kong, Fanlei, et al.
Publicado: (2020)

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
por: Attili, Ilaria, et al.
Publicado: (2023)

Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
por: Conibear, John
Publicado: (2020)

Burden of Alcoholic Liver Disease: Bhutan Scenario
por: Wangchuk, Pelden
Publicado: (2018)

Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer
por: Zhou, Mengting, et al.
Publicado: (2019)

The Thorny Side of Addiction: Adaptive Plasticity and Dendritic Spines
por: Mulholland, Patrick J., et al.
Publicado: (2007)

Circadian Rhythms, the Mesolimbic Dopaminergic Circuit, and Drug Addiction
por: McClung, Colleen A.
Publicado: (2007)

Role of long non‐coding RNA in drug resistance in non‐small cell lung cancer
por: Wang, Leirong, et al.
Publicado: (2018)

Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors
por: Wang, Zi‐Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_avi1p5hm2quu91q4k79n99ajhk